Epoetin alfa--focus on optimal hematocrit. Case study of the anemic patient.

Abstract

Epoetin alfa therapy has dramatically improved therapeutic responses and outcomes for anemic patients with end-stage renal disease. This article examines clinical evidence supporting the correlation between patient outcomes and a higher hematocrit and addresses some of the barriers that may hinder optimal patient outcomes.

• Authors: W R Hendrix
• Journal: ANNA journal (ANNA J) Vol. 23 Issue 1 Pg. 46-9 (Feb 1996) ISSN: 8750-0779 [Print] United States
• PMID: 8702361 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Erythropoietin

Topics

• Activities of Daily Living
• Anemia (blood, etiology, therapy)
• Erythropoietin (therapeutic use)
• Female
• Hematocrit
• Humans
• Kidney Failure, Chronic (complications)
• Middle Aged
• Quality of Life